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Abstract:  65 
Background: CD4 cell recovery following first-line combination antiretroviral treatment 66 
(cART) is poorer in HIV-2 than in HIV-1 positive (+) patients. Only large comparisons may 67 
allow adjustments for demographic and pretreatment plasma viral load (pVL). 68 
Methods: ART naïve HIV-positive (HIV+) adults from two European multi-cohort 69 
collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they 70 
started first-line cART (without non-nucleoside reverse transcriptase inhibitors or fusion 71 
inhibitors) between 1997 and 2011. Patients without at least 1 CD4 cell count before start of 72 
cART, without a pretreatment pVL and with missing a priori defined covariables were 73 
excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models.  74 
Results: We included 185 HIV-2+ and 30,321 HIV-1+ patients, median age of 46 (IQR: 36; 75 
52) and 37 (IQR: 31; 44) years, respectively. Median observed pretreatment CD4 cell 76 
counts/mm3 were 203 (95%CI: 100; 290) in HIV-2+ and 223 (95%CI: 100; 353) in HIV-1+ 77 
patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 78 
(95%CI: 77; 134) in HIV-2+ and +202 (95%CI: 199; 205) in HIV-1+patients, an observed 79 
difference of 97 cells/mm3 in one year. In adjusted analysis, mean CD4 cell increase was 80 
overall 25 CD4 cells/mm3/year lower (95% CI: 5; 44; P=0.0127) in HIV-2+ compared with 81 
HIV-1+ patients.  82 
Conclusions: Poorer CD4 cell increase during first-line cART was observed in HIV-2+ 83 
patients even after adjusting for pretreatment pVL and other potential confounders. Our 84 
results underline the need to identify more potent therapeutic regimens or strategies against 85 
HIV-2. 86 
  87 
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Background  88 
HIV-2 is less prevalent than HIV-1 and HIV-2 positive (+) individuals live mainly in West 89 
Africa, followed by Angola, Mozambique, Europe (primarily Portugal and France). 1 HIV-2 90 
infection is characterized by a lower plasma viral load (pVL) and a slower clinical 91 
progression. 2-7 Antiretroviral therapy options for HIV-2 are restricted due to its natural 92 
resistance to NNRTIs and fusion inhibitors, and because some PIs have shown lower 93 
efficacy. 8-11  94 
The 2013 WHO guidelines for treatment of HIV-2 infection recommended either triple NRTIs 95 
or two NRTIs combined with a ritonavir-boosted PI (PI/r) as first-line combination ART 96 
(cART), with a lopinavir-containing regimen as preferred option. 12, 13 In Europe, 97 
recommended first line cART regimen for HIV-2 infection consisted of two NRTIs and one PI 98 
or one PI/r since 2010. 14, 15 Of note, the conduct of a randomized clinical trial designed to 99 
inform about optimal cART strategies for HIV-2 therapy is not feasible in Europe due to the 100 
low prevalence of HIV-2 infection, but is ongoing in West Africa.  101 
CD4 cell recovery in HIV-2+ patients receiving first-line cART has been reported to be lower 102 
and slower than in HIV-1+ patients. 16-18 Two observational studies have reported a better 103 
immunological response in HIV-2+ patients with a PI/r based regimen compared to a triple 104 
NRTI regimen. 19, 20  105 
Comparative studies between HIV-1 and HIV-2 are often hampered by the small number of 106 
patients infected with HIV-2 under similar standardized follow-up. 3, 21 Contradictory results 107 
regarding CD4 cell recovery have been reported when pre-treatment pVL was taken into 108 
account. 3, 21, 22 The lower replication rate of HIV-2 has been hypothesized as one possible 109 
explanation leading to a poorer CD4 response to therapy. We compared immunological 110 
outcome in HIV-2- and HIV-1+ patients under standard follow-up in Europe, by adjusting for 111 
pretreatment plasma viral load levels at initiation of first cART, and other potential 112 
confounders.  113 
 114 
Methods  115 
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Data collection 116 
COHERE (HIV-1+ patients) and ACHIeV2e (HIV-2+ patients) are prospective, multinational, 117 
observational cohort collaborations. Data were pooled in the COHERE in EuroCoord 2011 118 
and ACHIEV2E 2011 data merger. COHERE is a collaboration of 40 cohorts from across 119 
Europe 23 and is part of the EuroCoord network (www.EuroCoord.net). The 23 cohorts 120 
participating in the present study through the COHERE network and the 9 cohorts 121 
participating through the ACHIeV2e network 24, 25 (listed in the Acknowledgments) submitted 122 
a defined dataset (patient demographics, current cART, CD4 counts and HIV RNA values, 123 
clinical status and events) to their network-specific Coordination Centre, using the HIV 124 
Cohort Data Exchange Protocol (HICDEP). 26 The final data set was merged at the Bordeaux 125 
Regional Coordinating Centre for COHERE and ACHIeV2e adhering to strict quality-126 
assurance guidelines and performing data quality checks. 127 
 128 
Study population 129 
Adult patients aged 18 or older infected either with HIV-2 or HIV-1 (dual seropositive and 130 
dual infected patients were excluded), who started a first-line cART regimen from 1997 to 131 
2011 were included in the analysis. HIV-2+ and HIV-1+ patients receiving a NNRTI- or fusion 132 
inhibitor containing regimen were not included because of the natural resistance of HIV-2 to 133 
these drug classes. 11 Observations were excluded if patients presented without one 134 
pretreatment CD4 cell count in a window of 6 months before start of cART 27 and without a 135 
pretreatment pVL based on quantification methods with a detection limit of 500 copies/mL or 136 
lower. We used a cut-off of 500 copies/mL (2.7 log10 copies/mL) to define undetectable pVL, 137 
as a consensus shared by the majority of contributing centers in the dataset. 24, 25 Only 138 
patients with complete data for potential confounders (listed below) were included in all 139 
analyses (Figure S1).  Criteria used to initiate therapy of HIV-2 infection were those fitting the 140 
national treatment guidelines of each contributing center effective at the time of cART start. 141 
The choice of antiretroviral combination was at the physician’s discretion based on these 142 
treatment guidelines. 143 
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Follow-up began at initiation of the first cART regimen (baseline). Follow-up was censored 144 
when the ART combination was modified for whatever reason, at death or at the last 145 
available CD4 cell counts whichever occurred first.  146 
 147 
Virological data and CD4 cell count 148 
All serological results, pVL values and CD4 cell count were obtained from laboratories of 149 
participating centers. HIV-1 and HIV-2 infection were diagnosed by ELISA tests confirmed by 150 
Western Blot. Quantification of HIV-2 viral load was assessed by in house methods; 25 the 151 
quality control assessments of quantification assays used by the ACHIeV2e network showed 152 
heterogeneity which improved from 2006 to 2011. 24, 25 Pre-treatment pVL and pre-treatment 153 
CD4 cell counts were defined as the closest measurement in a window of 6 months before 154 
cART start. 155 
 156 
Statistical analysis  157 
We studied the effect of the HIV-type on CD4 cell count at initiation of first cART (intercept) 158 
and on CD4 cell count change cells/mm3/year (slope) using linear mixed effect models with a 159 
random intercept and a random slope. The correlation between individual baseline CD4 160 
value(s) and the subsequent CD4 slope(s) was handled through an unstructured covariance 161 
matrix of random effects. We checked the underlying model assumptions (normality and 162 
homoscedasticity of residuals). 28  163 
We studied the effect of the following a priori defined covariables on CD4 cell count at cART 164 
initiation and on CD4 cell count change by introducing an interaction term with the slope: 165 
HIV-type (HIV-2 versus HIV-1 – main exposure variable), pVL as a continuous covariable 166 
(log10 copies/mL with imputation of the limit of detection for undetectable pVL), age (per 10-167 
year increase), sex, geographic origin (Europe, Africa, Asia, other/unknown), HIV 168 
transmission route (heterosexual, homosexual, drug use, other /unknown), prior AIDS 169 
diagnosis, cART regimen (two NRTIs + 1 ritonavir-boosted PI (other than lopinavir/r and 170 
darunavir/r), two NRTIs + lopinavir/r or darunavir/r, three NRTIs, other ART combinations 171 
Page 7 of 25
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
(mainly two or three NRTIs + an unboosted PI or combinations with integrase inhibitors), 172 
period of cART initiation (1998-1999, 2000-2001, 2002-2003, 2004-2005, 2006-2007, 2008-173 
2009, 2010-2011) and time between HIV diagnosis and cART start. The slope was 174 
additionally adjusted for pre-treatment CD4 cell count (per 100 cells/mm3 increase).  175 
Stratified and subgroup analyses 176 
For all stratified or subgroup analyses described below we used the linear mixed regression 177 
models adjusted for the same covariables described above. Our main hypothesis was related 178 
to the potential of differences in pVL which might explain the differences of CD4 cell count 179 
evolution between HIV-2 + and HIV-1+ patients. To explore the stability of estimations, we 180 
further restricted the analysis to patients with a baseline pVL measured by a test with a limit 181 
of 100 copies/mL or lower. We explored whether the effect of the virus type (HIV-2 or HIV-1) 182 
on CD4 cell response was modified by the level of baseline pVL by testing homogeneity of 183 
the association between HIV-type and CD4 cell count evolution across baseline pVL strata 184 
(pVL <500 and ≥500 copies/mL) by integrating an interaction term in the linear mixed model.  185 
We stratified the analyses of immunological response according to the type of cART 186 
received, i.e. three NRTIs, two NRTIs combined with a ritonavir-boosted PI (other than 187 
lopinavir/r and darunavir/r), and two NRTIs combined with either lopinavir/r or darunavir/r, to 188 
assess if the cART regimen had an effect on the association between HIV-type and CD4 cell 189 
response by testing homogeneity of the association HIV-type and CD4 cell count evolution 190 
across baseline cART regimen. The three categories of cART were chosen because these 191 
cART regimens were those recommended by WHO during the study period. 13  192 
 193 
Results are presented for 12 months of follow-up after cART initiation but analyses are based 194 
on all available CD4 cell counts after cART initiation up to 115 and 150 months in HIV-2+ and 195 
HIV-1+ patients.  We described categorical variables with frequencies (%) and continuous 196 
variables with median (IQR). CD4 cell count changes were described with means and 95% 197 
confidence intervals after having assessed the normality assumption. Categorical variables 198 
were compared between HIV-2+ and HIV-1+ (included and excluded) patients using chi-199 
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square tests or Fisher’s exact test as appropriate. Quantitative variables were compared 200 
between groups using the Wilcoxon-Mann-Whitney test. 201 
All analyses were performed with SAS 9.2 (SAS Institute, Cary, NC, USA). 202 
 203 
Results 204 
Characteristics at cART start 205 
In the ACHIeV2e dataset 243 HIV-2+ patients full-filled inclusion criteria; of those, 58 were 206 
excluded for a total of 185 HIV-2+ patients in the analyses (Figure S1). We observed no 207 
significant difference between included and excluded HIV-2+ patients (Table S1).  In the 208 
COHERE dataset 66,483 HIV-1+ patients full-filled inclusion criteria; of these 36,162 were 209 
excluded for a total of 30,231 HIV-1+ patients in the analyses (Figure S1). Included HIV-1+ 210 
patients were less often of European origin, less often injection drug users, more often 211 
treated with two NRTIs combined with either lopinavir/r or darunavir/r than non-included 212 
patients (Table S1).  213 
Baseline characteristics are presented in Table 1. At start of first-line cART, HIV-2+ patients 214 
were significantly older (median age 46 (IQR: 36; 52) years) compared with HIV-1+ patients 215 
(37 (32; 44) years; P<0.0001). The proportion of HIV-2+ patients with a pVL below 500 216 
copies/mL was significantly higher compared with patients infected with HIV-1 (60% versus 217 
12%, P<0.0001). Median pVL (IQR) was 3.2 log10 copies/mL (2.2; 4.2) and 4.8 log10 218 
copies/mL (4.0; 5.4) in HIV-2+ and HIV-1+ patients, respectively. Median time between HIV 219 
diagnosis and cART start was significantly longer in HIV-2+ compared with HIV-1+ patients 220 
(1.0 years versus 0.6 years, P=0.0390). Two NRTIs plus lopinavir/r or darunavir/r was the 221 
most frequent cART regimen in HIV-2+ and HIV-1+ patients (43% and 36.5% respectively) 222 
followed by two NRTIs plus other boosted PIs (23.8% versus 22.6%). Three NRTIs were 223 
prescribed in 13% and 7.2% of HIV-2+ and HIV-1+ patients, respectively. Median pre-224 
treatment CD4 cell count was similar in HIV-2+ versus HIV-1+ patients (203 cells/mm3; IQR: 225 
100; 290 versus 223; IQR: 100; 353) cells/mm3, P=0.1480). After adjustment for a priori 226 
defined confounding covariables a significant difference in CD4 cell count at cART initiation 227 
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remained between HIV-2+ and HIV-1+ patients. HIV-2+ patients had 56 CD4 cells/mm3 less 228 
at cART initiation compared to HIV-1+ patients (P<0.0001). 229 
 230 
Follow-up data 231 
Median follow-up from first-line cART start until treatment modification, death or last available 232 
CD4 cell count was 10 (IQR: 1; 27) and 8 months (IQR: 2; 21) in HIV-2+ and HIV-1+ patients 233 
(P=0.0412). A median of 3 (2; 8) and 4 (2; 8) CD4 cell counts per HIV-2+ and HIV-1+ patient 234 
were available, respectively (P=0.1555). Among HIV-2+ and HIV-1+ patients, 4.3% and 5.4% 235 
were lost to follow up (P=0.5017) and 1.1% and 1.7% died (P=0.5344), respectively.  236 
 237 
CD4 cell count evolution  238 
In patients still followed at 12 months, median observed CD4 cell counts at 12 months were 239 
265 (IQR: 182; 420) in HIV-2+ and 404 (IQR: 262; 571) in HIV-1+ patients (Figure 1). Mean 240 
observed change in CD4 cell count from start of cART to M12 was +105 (95%CI: 77 to 134] 241 
in HIV-2+ and +202 (95%CI: 199 to 205) in HIV-1+ patients which is an observed difference 242 
of 97 CD4 cells/mm3 in CD4 cell increase in one year. 243 
After adjusting for pre-treatment pVL only, the mean CD4 cell count increase remained 244 
significantly lower in HIV-2+ compared with HIV-1+ patients (difference of -41 CD4 245 
cells/mm3/year (95% CI: -20 to -61); P<0.0001). This difference persisted (difference of -25 246 
CD4 cells/mm3/year (95% CI: -44  to -5); P=0.0127) after adjustment for pre-treatment pVL 247 
and the other potential confounders (Table 2). All a priori defined covariables were 248 
significantly and independently associated with CD4 cell count change. Of note, 249 
irrespectively of the HIV type and all other variables included in the model, patients receiving 250 
three NRTIs had on average a significantly lower CD4 cell increase when compared with 251 
patients receiving a boosted PI based cART regimen (difference in slope of -34 252 
cells/mm3/year; 95% CI: -40 to -26; P<0.0001; Table 2).  253 
 254 
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All subgroup and stratified analyses showed stable results. When considering only patients 255 
with a baseline pVL measured by an assay with a detection limit of 100 copies/mL or lower 256 
(HIV-1 n=27,594; HIV-2 n=129), CD4 cell increase was lower in HIV-2+ patients in adjusted 257 
analysis (difference of -29 CD4 cells/mm3/year (95% CI: -4 to -53); P=0.0227). The effect of 258 
HIV type on CD4 cell count response was not modified by baseline pVL, thus the effect of 259 
HIV on CD4 cell count response did not differ in those with a baseline pVL of 500 copies/mL 260 
or more (HIV-1 n=26,602; HIV-2 n=75) and those with a baseline pVL below 500 copies/mL 261 
(HIV-1 n=3,719; HIV-2 n=110) (P=0.1711). Differences in CD4 cell increase between HIV-2+ 262 
and HIV-1+ patients were not modified by the initial cART regimen (interaction test: 263 
P=0.9093).  264 
 265 
Discussion 266 
The reasons for the previously reported poorer immunological response to first line cART in 267 
HIV-2+ patients are still poorly understood. Using data from two large European 268 
observational cohort collaborations, we found a significantly lower CD4 cell increase after 269 
starting first-line cART between HIV-2+ compared with HIV-1+ patients (i.e. observed 270 
difference of 97 CD4 cells/mm3). The difference in CD4 cell count increase between HIV-2+ 271 
and HIV-1+ patients remained significant after adjusting for pre-treatment pVL, cART 272 
regimen and other main confounders (i.e. difference of 25 cells/mm3/year). Furthermore, the 273 
difference between HIV-2 and HIV-1 was not modified by the cART regimen.   274 
ART regimens have been mainly developed for and validated in HIV-1+ patients; their 275 
potency is likely to be different in HIV-2+ patients. Lower potency of several PIs, such as 276 
nelfinavir, fosamprenavir, and atazanavir has been reported by phenotypic studies. 8 The 277 
replication cycle of HIV-2 is clearly different from that of HIV-1. HIV-2 pVL is more often 278 
below the threshold of detectability, and lower when quantified, compared to HIV-1 pVL, 279 
even at advanced disease stages. Total pro-viral DNA is very similar in HIV-1- and HIV-2 280 
infection after adjustment for CD4 cell count. 29-32 This suggests at least a blockade of HIV-2 281 
replication at the post-integration level and may explain the differences between HIV-1 and 282 
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HIV-2 with regard to the potency of PIs. Of note, the difference in CD4 increase between 283 
HIV-2 and HIV-1 was smaller (i.e. difference of 25 cells/mm3/year) after adjusting for pre-284 
treatment pVL, cART regimen and other main confounders but remained significant. 285 
Furthermore, our results were robust after adjustement for pVL as a time-dependent 286 
covariable.  287 
The time between HIV-diagnosis and cART initiation, known to contribute to a poorer 288 
immunological response to cART, was longer in HIV-2+ compared to HIV-1+ patients. This 289 
longer delay is probably due to the slower CD4 cell decrease and the longer asymptomatic 290 
stage distinguishing natural history of HIV-2 infection. 3 Nonetheless, CD4 cell increase 291 
remained significantly lower in HIV-2+ patients in our analysis adjusted for this delay 292 
between HIV-diagnosis and cART initiation. For both HIV-1 and HIV-2 infections initiation of 293 
cART was recommended at more advanced stages during the study period than currently is 294 
the case. Criteria used to initiate antiretroviral therapy in HIV-2+ patients were those fitting 295 
the national guidelines of each contributing center effective at the time of cART start. These 296 
guidelines were consistent across Europe and included CDC stages B and C, CD4 297 
lymphopenia and HIV-2 RNA levels above the detection limit of the quantification assay; the 298 
level of CD4 lymphopenia defined for cART indication in HIV-2 infection was lower than that 299 
defined for HIV-1 infection, and may also explain the difference observed in pre-treatment 300 
CD4 cell counts. Of note, median CD4 cell count was 203 cells/mm3 in HIV-2+ patients at 301 
cART start, lower than in HIV-1+ patients, similar to that reported at ART start in the IeDEA-302 
West Africa HIV-2 cohort study (i.e. 166 cells/mm3). 33 It has since been demonstrated that 303 
earlier treatment of HIV-1 infection is the best strategy for successful immune restoration.34 304 
Long term non-progressors account for 6% of the whole asymptomatic HIV-2 population, 305 
applying the same methodology as used to determine their proportion in HIV-1 infected 306 
patients.35 Among the remaining 94% there are patients with slightly progressive infection, 307 
who might benefit from earlier treatment leading to a better immune restoration.  308 
We found an overall significantly lower CD4 cell increase in patients receiving a three NRTIs 309 
regimen compared with those receiving a ritonavir-boosted PI based regimen. These findings 310 
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obviously confirm the results of a European observational study which partly included the 311 
same HIV-2 infected patients,20 but also those of a recent West African study. 19 Direct 312 
comparisons of different treatment regimens in observational studies are challenging and the 313 
gold standard design for such analyses and for evidence-based conclusions are randomized 314 
clinical trials. Such trials are not realisable in Europe due to the restricted size of potentially 315 
eligible HIV-2 infected patients living there. However, we report for the first time a 316 
comparison of CD4 cell response to first line cART in a large population of HIV-2 and HIV-1 317 
infected patients under standardized routine follow-up in Europe allowing us to adjust the 318 
comparison for initial pVL levels, cART regimen, region of origin, and other patients’ 319 
characteristics such as pre-treatment CD4 cell count and previous AIDS diagnosis, and for 320 
calendar periods of cART initiation.  321 
Chronic immune activation and inflammation markers have been linked to disease 322 
progression in HIV-1+ 36, 37 and HIV-2+ patients. 38-40 Differences in CD4 cell count response 323 
to first cART may be linked to differences in the underlying pathogenicity of these two viruses 324 
regarding immune activation. However, chronic immune activation is directly linked to pVL 39, 325 
41 and in our comparison of immune response we controlled for pVL in various ways. Of note, 326 
it has been shown that HIV-2 non-progression is associated with better immune response to 327 
the virus, less immune activation, broad neutralizing antibody response; nevertheless we do 328 
not know what came first: the particularities of HIV-2 replication or the immune response.  329 
There are several limitations to our analyses. Differences in immunological outcome between 330 
HIV-1 and HIV-2 may have been observed due to unmeasured confounding factors. We 331 
cannot completely rule out a selection bias as we did not analyze pretreatment slopes of 332 
CD4 cells decrease in HIV-1 and HIV-2 populations. We were neither able to adjust for 333 
hepatitis B and/or hepatitis C co-infection, although we adjusted for geographical origin and 334 
transmission risk group which are closely linked to hepatitis B and C seroprevalences. 335 
Furthermore, follow-up was quite short and may hamper the extrapolation of our results to 336 
the long term.  337 
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Our study has several strengths. This is a large study comparing CD4 cell dynamics between 338 
HIV-2+ and HIV-1+ patients after start of first-line cART. The data quality was assured 339 
through two large European collaborative networks adhering to strict quality control checks 340 
which allowed us to adjust our comparative analysis for the major confounding variables. 341 
Furthermore, we could confirm our main findings in subgroup and stratified analyses showing 342 
the robustness of the results and the absence of effect modification by initial pVL and cART 343 
regimen. 344 
Differences in CD4 cell dynamics between HIV-2 and HIV-1 were consistent in all analyses 345 
with a poorer CD4 cell increase after start of treatment in HIV-2+ patients, even after 346 
adjustment on plasma viral load. Our results underline the need to identify other factors 347 
contributing to this lower CD4 cell response such as more potent drugs against HIV-2, 348 
adapted to the particularities of the virus replication when compared with HIV-1, in order to 349 
improve case management. 350 
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 438 
CLINICAL CENTRES 439 
*denotes site coordinating physician 440 
Academic Medical Centre of the University of Amsterdam: HIV treating physicians: J.M. 441 
Prins*, T.W. Kuijpers, H.J. Scherpbier, J.T.M. van der Meer, F.W.M.N. Wit, M.H. Godfried, P. 442 
Reiss, T. van der Poll, F.J.B. Nellen, S.E. Geerlings, M. van Vugt, D. Pajkrt, J.C. Bos, W.J. 443 
Wiersinga, M. van der Valk, A. Goorhuis, J.W. Hovius, A.M. Weijsenfeld. HIV nurse 444 
consultants: J. van Eden, A. Henderiks, A.M.H. van Hes, M. Mutschelknauss, H.E. Nobel, 445 
F.J.J. Pijnappel. HIV clinical virologists/chemists: S. Jurriaans, N.K.T. Back, H.L. Zaaijer, B. 446 
Berkhout, M.T.E. Cornelissen, C.J. Schinkel, X.V. Thomas. Admiraal De Ruyter 447 
Ziekenhuis, Goes: HIV treating physicians: M. van den Berge, A. Stegeman. HIV nurse 448 
consultants: S. Baas, L. Hage de Looff. HIV clinical virologists/chemists: D. Versteeg. 449 
Catharina Ziekenhuis, Eindhoven: HIV treating physicians: M.J.H. Pronk*, H.S.M. 450 
Ammerlaan. HIV nurse consultants: E.S. de Munnik. HIV clinical virologists/chemists: A.R. 451 
Jansz, J. Tjhie, M.C.A. Wegdam, B. Deiman, V. Scharnhorst. Emma Kinderziekenhuis: HIV 452 
nurse consultants: A. van der Plas, A.M. Weijsenfeld. Erasmus Medisch Centrum, 453 
Rotterdam: HIV treating physicians: M.E. van der Ende*, T.E.M.S. de Vries-Sluijs, E.C.M. 454 
van Gorp, C.A.M. Schurink, J.L. Nouwen, A. Verbon, B.J.A. Rijnders, H.I. Bax, M. van der 455 
Feltz. HIV nurse consultants: N. Bassant, J.E.A. van Beek, M. Vriesde, L.M. van Zonneveld. 456 
Data collection: A. de Oude-Lubbers, H.J. van den Berg-Cameron, F.B. Bruinsma-Broekman, 457 
J. de Groot, M. de Zeeuw- de Man. HIV clinical virologists/chemists: C.A.B. Boucher, M.P.G 458 
Koopmans, J.J.A van Kampen. Erasmus Medisch Centrum–Sophia, Rotterdam: HIV 459 
treating physicians: G.J.A. Driessen, A.M.C. van Rossum. HIV nurse consultants: L.C. van 460 
der Knaap, E. Visser. Flevoziekenhuis, Almere: HIV treating physicians: J. Branger*, A. 461 
Rijkeboer-Mes. HIV nurse consultant and data collection: C.J.H.M. Duijf-van de Ven. 462 
HagaZiekenhuis, Den Haag: HIV treating physicians: E.F. Schippers*, C. van Nieuwkoop. 463 
HIV nurse consultants: J.M. van IJperen, J. Geilings. Data collection: G. van der Hut. HIV 464 
clinical virologist/chemist: P.F.H. Franck. HIV Focus Centrum (DC Klinieken): HIV treating 465 
physicians: A. van Eeden*. HIV nurse consultants: W. Brokking, M. Groot, L.J.M. Elsenburg. 466 
HIV clinical virologists/chemists: M. Damen, I.S. Kwa. Isala, Zwolle: HIV treating physicians: 467 
P.H.P. Groeneveld*, J.W. Bouwhuis. HIV nurse consultants: J.F. van den Berg, A.G.W. van 468 
Hulzen. Data collection: G.L. van der Bliek, P.C.J. Bor. HIV clinical virologists/chemists: P. 469 
Bloembergen, M.J.H.M. Wolfhagen, G.J.H.M. Ruijs. Leids Universitair Medisch Centrum, 470 
Leiden: HIV treating physicians: F.P. Kroon*, M.G.J. de Boer, M.P. Bauer, H. Jolink, A.M. 471 
Vollaard. HIV nurse consultants: W. Dorama, N. van Holten. HIV clinical virologists/chemists: 472 
E.C.J. Claas, E. Wessels. Maasstad Ziekenhuis, Rotterdam: HIV treating physicians: J.G. 473 
den Hollander*, K. Pogany, A. Roukens. HIV nurse consultants: M. Kastelijns, J.V. Smit, E. 474 
Smit, D. Struik-Kalkman, C. Tearno. Data collection: M. Bezemer, T. van Niekerk. HIV clinical 475 
virologists/chemists: O. Pontesilli. 476 
Maastricht UMC+, Maastricht: HIV treating physicians: S.H. Lowe*, A.M.L. Oude Lashof, D. 477 
Posthouwer. HIV nurse consultants: R.P. Ackens, J. Schippers, R. Vergoossen. Data 478 
collection: B. Weijenberg-Maes. HIV clinical virologists/chemists: I.H.M. van Loo, T.R.A. 479 
Havenith. MC Slotervaart, Amsterdam: HIV treating physicians: J.W. Mulder, S.M.E. 480 
Vrouenraets, F.N. Lauw. HIV nurse consultants: M.C. van Broekhuizen, H. Paap, D.J. 481 
Vlasblom. HIV clinical virologists/chemists: P.H.M. Smits. MC Zuiderzee, Lelystad: HIV 482 
treating physicians: S. Weijer*, R. El Moussaoui. HIV nurse consultant: A.S. Bosma. 483 
Medisch Centrum Alkmaar: HIV treating physicians: W. Kortmann*, G. van Twillert*, J.W.T. 484 
Cohen Stuart, B.M.W. Diederen. HIV nurse consultant and data collection: D. Pronk, F.A. 485 
van Truijen-Oud. HIV clinical virologists/chemists: W. A. van der Reijden, R. Jansen. 486 
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Medisch Centrum Haaglanden, Den Haag: HIV treating physicians: E.M.S. Leyten*, L.B.S. 487 
Gelinck. HIV nurse consultants: A. van Hartingsveld, C. Meerkerk, G.S. Wildenbeest. HIV 488 
clinical virologists/chemists: J.A.E.M. Mutsaers, C.L. Jansen. Medisch Centrum 489 
Leeuwarden, Leeuwarden: HIV treating physicians: M.G.A.van Vonderen*, D.P.F. van 490 
Houte, L.M. Kampschreur. HIV nurse consultants: K. Dijkstra, S. Faber. HIV clinical 491 
virologists/chemists: J Weel. Medisch Spectrum Twente, Enschede: HIV treating 492 
physicians: G.J. Kootstra*, C.E. Delsing. HIV nurse consultants: M. van der Burg-van de 493 
Plas, H. Heins. Data collection: E. Lucas. Onze Lieve Vrouwe Gasthuis, Amsterdam: HIV 494 
treating physicians: K. Brinkman*, P.H.J. Frissen, W.L. Blok, W.E.M. Schouten, G.E.L. van 495 
den Berk. HIV nurse consultants: C.J. Brouwer, G.F. Geerders, K. Hoeksema, M.J. Kleene, 496 
I.B. van der Meché, A.J.M. Toonen, S. Wijnands. HIV clinical virologists: M. Damen, D. Kwa. 497 
Radboudumc, Nijmegen: HIV treating physicians: P.P. Koopmans, M. Keuter, A.J.A.M. van 498 
der Ven, H.J.M. ter Hofstede, A.S.M. Dofferhoff, R. van Crevel. HIV nurse consultants: M. 499 
Albers, M.E.W. Bosch, K.J.T. Grintjes-Huisman, B.J. Zomer. HIV clinical virologists/chemists: 500 
F.F. Stelma, J. Rahamat-Langendoen. HIV clinical pharmacology consultant: D. Burger. 501 
Rijnstate, Arnhem: HIV treating physicians: C. Richter*, E.H. Gisolf, R.J. Hassing. HIV 502 
nurse consultants: G. ter Beest, P.H.M. van Bentum, N. Langebeek. HIV clinical 503 
virologists/chemists: R. Tiemessen, C.M.A. Swanink. Sint Lucas Andreas Ziekenhuis, 504 
Amsterdam: HIV treating physicians: J. Veenstra*, K.D. Lettinga. HIV nurse consultants: M. 505 
Spelbrink, H. Sulman. Data collection: M. Spelbrink, E. Witte. HIV clinical 506 
virologists/chemists: M. Damen, S.Q. van Veen. Spaarne Gasthuis, Haarlem: HIV treating 507 
physicians: S.F.L. van Lelyveld*, R. Soetekouw. HIV nurse consultants: N. Hulshoff, L.M.M. 508 
van der Prijt, J. van der Swaluw. Data collection: N. Bermon. HIV clinical virologists/chemists: 509 
W.A. van der Reijden, R. Jansen, B.L. Herpers, D.Veenendaal. Stichting Medisch Centrum 510 
Jan van Goyen, Amsterdam: HIV treating physicians: D.W.M. Verhagen. HIV nurse 511 
consultants: M. van Wijk. St Elisabeth Ziekenhuis, Tilburg: HIV treating physicians: M.E.E. 512 
van Kasteren*, A.E. Brouwer. HIV nurse consultants and data collection: B.A.F.M. de Kruijf-513 
van de Wiel, M. Kuipers, R.M.W.J. Santegoets, B. van der Ven. HIV clinical 514 
virologists/chemists: J.H. Marcelis, A.G.M. Buiting, P.J. Kabel. Universitair Medisch 515 
Centrum Groningen, Groningen: HIV treating physicians: W.F.W. Bierman*, H. Scholvinck, 516 
S. van Assen, K.R. Wilting, Y. Stienstra. HIV nurse consultants: H. de Groot-de Jonge, P.A. 517 
van der Meulen, D.A. de Weerd, J. Ludwig-Roukema. HIV clinical virologists/chemists: 518 
H.G.M. Niesters, A. Riezebos-Brilman, C.C. van Leer-Buter, M. Knoester. Universitair 519 
Medisch Centrum Utrecht, Utrecht: HIV treating physicians: A.I.M. Hoepelman*, M.M.E. 520 
Schneider, T. Mudrikova, P.M. Ellerbroek, J.J. Oosterheert, J.E. Arends, R.E. Barth, M.W.M. 521 
Wassenberg, E.M. Schadd. HIV nurse consultants: D.H.M. van Elst-Laurijssen, E.E.B. van 522 
Oers-Hazelzet, J. Patist, S. Vervoort, Data collection: M. van Berkel. HIV clinical 523 
virologists/chemists: R. Schuurman, F. Verduyn-Lunel, A.M.J. Wensing. VU medisch 524 
centrum, Amsterdam: HIV treating physicians: E.J.G. Peters*, M.A. van Agtmael, M. 525 
Bomers, J. de Vocht. HIV nurse consultants: M. Heitmuller, L.M. Laan. HIV clinical 526 
virologists/chemists: A.M. Pettersson, C.M.J.E. Vandenbroucke-Grauls, C.W. Ang. 527 
Wilhelmina Kinderziekenhuis, UMCU, Utrecht: HIV treating physicians: S.P.M. Geelen, 528 
T.F.W. Wolfs, L.J. Bont. HIV nurse consultants: N. Nauta. 529 
 530 
COORDINATING CENTRE  531 
Stichting HIV Monitoring Director: P. Reiss. Data analysis: D.O. Bezemer, A.I. van Sighem, 532 
C. Smit. Data management and quality control: S. Zaheri, M. Hillebregt, A. de Jong. Data 533 
monitoring: D. Bergsma, P. Hoekstra, A. de Lang, M. Berkhout, S. Grivell, A. Jansen, M.J. 534 
Rademaker, M. Raethke. Data collection: L. de Groot, M. van den Akker, Y. Bakker, M. 535 
Broekhoven, E. Claessen, A. El Berkaoui, E. Kruijne, C. Lodewijk, R. Meijering, L. 536 
Munjishvili, B. Peeck, C. Ree, R. Regtop, Y. Ruijs, T. Rutkens, M. Schoorl, S. Schnörr, E. 537 
Tuijn, L. Veenenberg, S. van der Vliet, T. Woudstra. Patient registration: B. Tuk. 538 
 539 
Portugal: Clinica Universitaria de Doenças Infecciosas, Lisbon (Francisco Antunes, Kamal 540 
Mansinho, Emilia Valadas).  541 
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Spain: Hospital Carlos III, Madrid (Vicente Soriano, Ana Trevino, Berta Rodes).  542 
Switzerland: Swiss HIV Cohort Study. The members of the Swiss HIV Cohort Study 543 
are  Barth J, Battegay M,  Bernasconi E, Böni J, Bucher HC, Bürgisser P,  Burton-Jeangros 544 
C, Calmy A, Cavassini M, Dubs R, Egger M, Elzi L, Fehr J, Flepp M, Francioli P (President of 545 
the SHCS), Furrer H (Chairman of the Clinical and Laboratory Committee), Fux CA, 546 
Gorgievski M, Günthard H (Chairman of the Scientific Board), Hasse B, Hirsch HH, Hirschel 547 
B, Hösli I, Kahlert C, Kaiser L, Keiser O, Kind C, Klimkait T, Kovari H, Ledergerber B, 548 
Martinetti G, Martinez de Tejada B, Müller N, Nadal D, Pantaleo G, Rauch A,  Regenass 549 
S, Rickenbach M (Head of Data Center), Rudin C (Chairman of the Mother & Child 550 
Substudy), Schmid P,Schultze D, Schöni-Affolter F,  Schüpbach J, Speck R,  Taffé P, Telenti 551 
A, Trkola A,  Vernazza P, von Wyl V, Weber R, Yerly S.  552 
 553 
Laboratories.  554 
Belgium: AIDS Reference Laboratory, Université Catholique de Louvain, AIDS Reference 555 
Laboratory, Brussels (Patrick Goubau, Jean Ruelle).  556 
France: Cellular immunology laboratory, Pitié-Salpétrière Hospital, Paris (Brigitte Autran); 557 
virology laboratory, Bichat–Claude Bernard Hospital, Paris (Françoise Brun-Vezinet, 558 
Florence Damond, Diane Descamps), Saint-Louis Hospital, Paris (François Simon).  559 
Italy: University of Milan, Department of Clinical Sciences "L. Sacco" (Claudia Balotta).  560 
Portugal: Hospital Egas Moniz, Lisbon (Ricardo Camacho, Perpetua Gomes); Clínica 561 
Universitária de Doenças Infecciosas e Parasitárias, Lisbon (Emília Valadas); Centro 562 
Hospitalar e Universitário de Coimbra, Coimbra (Vitor Duque). 563 
Spain: Laboratory of Molecular Biology, Infectious Diseases Department, Hospital Carlos III, 564 
Madrid (Ana Treviño & Vincent Soriano).  565 
Switzerland: Laboratories of the Swiss HIV Cohort Study (resp. Jürg Böni). 566 
 567 
Coordinating centre. France: ANRS Clinical Trials Unit INSERM U1219 (Céline Roy, 568 
Geneviève Chêne, Alexandra Ozanne, Audrey Taieb). 569 
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 695 
Figure Legends 696 
Figure 1:  Median observed CD4 cell counts after first line cART initiation in HIV-2 and HIV-1 697 
infected patients up to 12 months of follow-up. Legend: vertical bars represent the 698 
interquartile range (IQR).   699 
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Table 1: Characteristics of patients at initiation of first cART 700 
 701 
Characteristics HIV-1 (n=30,231) HIV-2 (n=185) P-value 
Median age in years (IQR) 37 (31;44) 46 (36;52) <0.0001 
Female, n (%) 8179 (27.1) 88 (47.6) <0.0001 
Region of origin, n (%)     <0.0001 
 Europe 16517 (54.6) 47 (25.4)  
 Africa 2495 (8.3) 130 (70.3)  
 Asia 413 (1.4) 2 (1.1)  
 Unknown/Other
a
 10806 (35.7) 6 (3.2)  
Transmission risk group, n (%)     <0.0001 
 Heterosexual  10783 (35.7) 154 (83.2)  
 Homo/bisexual male 11825 (39.1) 7 (3.8)  
 Injecting drug user 4887 (16.2) 2 (1.1)  
 Mother-to-child  26 (0.1)    
 Unknown/other 2710 (9.0) 22 (11.9)  
Prior AIDS diagnosis n (%) 7169 (23.7) 42 (22.7) 0.7471 
First line cART regimen, n (%)     0.0002 
   2 NRTIs + 1 PI/rtv (not LPV or 
DRV) 
6823 (22.6) 44 (23.8)  
    2 NRTIs + LPV/rtv or DRV/rtv 11039 (36.5) 79 (42.7)  
    3 NRTIs 2180 (7.2) 24 (13)  
    Other combinations 10189 (33.7) 38 (20.5)  
Period of treatment initiation, n (%)     <0.0001 
    1998-1999 6292 (20.8) 13 (7.0)  
    2000-2001 3708 (12.3) 19 (10.3)  
    2002-2003 3810 (12.6) 32 (173)  
    2004-2005 4613 (15.3) 34 (18.4)  
    2006-2007 5557 (18.4) 44 (23.8)  
    2008-2009 5102 (16.9) 30 (16.2)  
    2010-2011 1149 (3.8) 13 (7.0)  
Pretreatment HIV RNA viral load       
<500 copies /ml, n (%) 3719 (12.3) 110 (59.5) <0.0001 
Median log10 copies/mL (IQR)* 4.8 (4.0;5.4) 3.2 (2.2;4.2) <0.0001 
Median pretreatment CD4 cell count 
cells/mm3 (IQR) 
223 (100;353) 203 (100;290) 0.1480 
Median delay beween first HIV 
seropositivity and cART start 
(years)** (IQR) 
0.61 (0.11;3.79) 0.97 (0.21;5.25) 0.0390 
 702 
Legend: cART: combination antitretroviral therapy; rtv, ritonavir boost; LPV, lopinavir; DRV, darunavir. 703 
Other regimens largely consisting of two or three NRTIs plus an unboosted PI or of combinations with 704 
integrase inhibitors (347 [1.1 %] HIV-1 infected and 7 HIV-2 [3.8%] infected patients were treated with 705 
an integrase inhibitor).aHIV-1: for 9,462 patients the geographical origin was reported as unknown and 706 
1,344 were from other regions (Oceania-not Australia, Australia and New Zealand, America, North 707 
America, Central and South America and Middle East); HIV-2: for 2 patients the geographical origin 708 
was reported as unknown and 2 patients were from America and 2 patients from Central and South 709 
America. *For patients with a viral load below the detection limit of the test, the detection limit has 710 
been imputed for the calculation.  711 
 712 
 713 
 714 
 715 
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Table 2: Estimated mean CD4 cell count differences at first line cART start and CD4 716 
cell count changes adjusted for all listed co-variables. For CD4 cell count changes, a 717 
negative value indicates a lower CD4 increase, and a positive value indicates a higher CD4 718 
increase. (N=30,231 for HIV-1 infected patients and N=185 for HIV-2 infected patients) 719 
  CD4 cell count at initiation of 
first cART (cells/mm3) 
CD4 cell count change 
(cells/mm
3
/year) 
Mean 95% CI P Mean 95% CI P 
Intercept/slope 533 518; 549 <0.0001 154 142; 166 0.0003 
HIV type        
 HIV-2 vs HIV-1 -56 -86; -26 <0.0001 -25 -44; -5 0.0127 
Pretreatment plasma viral load (per 
additional 1 log10 copies/mL) 
 
-26 
 
-28; -24 
 
<0.0001 
 
9 
 
8; 10 
 
<0.0001 
Age at treatment initiation (per 
additional 10 years) 
 
-22 
 
-25; -20 
 
<0.0001 
 
-9 
     
-10;  -7 
  
<0.0001 
Sex       
 Female vs Male 26 19; 32 <0.0001 10 6; 15 <0.0001 
Geographic origin    <0.0001   <0.0001 
Europe (ref)       
Africa -31 -40; -22  -25 -32; 19  
Asia -53 -73; -33  -7 -21; 6  
Other or unknown -18 -23; -13  -4 -8; -1  
Transmission group    <0.0001   <0.0001 
Heterosexual (ref)       
Homo/bisexual male 53 47; 59  9 4; 13  
Injecting drug user -25 -33; -18  -16 -21; -10  
Other or unknown -9 -17; 0  -12 -18; -6  
Prior AIDS diagnosis       
 Yes vs No -126 -132; -121 <0.0001 6 2; 10 0.0047 
cART regimen    <0.0001   <0.0001 
 2 NRTIs + 1 PI/rtv (ref)       
 2 NRTIs + LPV/rtv or DRV/rtv -9 -15; -3  4 -1; 8  
 3 NRTIs 53 42; 63  -34 -40; -26  
 Other combinations 24 17; 32  -5 -11; 0.5  
Period of cART initiation    <0.0001   <0.0001 
1998-1999 -7 -16; 2  -53 -60; -46  
2000-2001 -26 -36; -17  -59 -66; -52  
2002-2003 -14 -23; -6  -56 -62; -49  
2004-2005 -17 -25; -9  -50 -57; -44  
2006-2007 3 -4; 11  -38 -44; -32  
2008-2009 (ref)       
2010-2011 -11 -24; 3  130 108; 153  
Delay beween first HIV seropositivity 
and cART start (per additional year) 
Pretreatment CD4 cell count (per 
additional 100 cells/mm
3
)* 
 
-0.8 
 
- 
 
-1.4; -0.3 
 
- 
 
0.0039 
 
- 
 
-1.1 
 
-2 
 
-1.5; -0.7 
 
-3; -1 
 
<0.0001 
 
<0.0001 
 720 
Legend: ref: reference category; cART: combination antitretroviral therapy; rtv, ritonavir boost; LPV, 721 
lopinavir; DRV, darunavir. Other regimens largely consisting of two or three NRTIs plus an unboosted 722 
PI or of combinations with integrase inhibitors.* The reported difference in CD4 cell count change is for 723 
a difference of 100 CD4 cells/mm3 at baseline, i.e. in a patient with 400 CD4 cells/mm3 the increase is 724 
of 2 cells less than compared to a patient with 300 CD4 cells/mm3. 725 
 726 
Page 23 of 25
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
  
 
 
 
 
254x190mm (96 x 96 DPI)  
 
 
Page 24 of 25
Journal of Antimicrobial Chemotherapy: under review
Journal of Antimicrobial Chemotherapy
Confidential: for peer review only
Supplementary Material 
COHERE/AVHIEV2E 
1 
 
 
Figure S1: Flowchart – COHERE in EuroCoord and ACHIEV2E project
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Table S1: Baseline characteristics of excluded compared with included HIV-1+ and HIV-2+ patients. 
 HIV-1 (N=66, 483) HIV-2 (N=243) 
Excluded Included P
a
 Excluded Included P
a
 
   
N =36,252 
  
N =30,231 
N =58   
N =185 
Median age in years (IQR) 38 (32;45) 37 (31;44) <0.0001 43 (34;53) 46 (36;52) 0.2862 
Sex, n (%)     <0.0001     0.0539 
   Male 24518 (67.6) 22052 (72.9)  22 (37.9) 97 (52.4)  
   Female 11724 (32.3) 8179 (27.1)  36 (62.1) 88 (47.6)  
   Unknown 10 (0)         
Geographic origin, n (%)     <0.0001     0.6340 
   Africa 6281 (17.3) 2495 (8.3)  45 (77.6) 130 (70.3)  
   Europe 7248 (20.0) 16517 (54.6)  12 (20.7) 47 (25.4)  
   Asia 310 (0.9) 413 (1.4)    2 (1.1)  
   Unknown/Other 22413 (61.8) 10806 (35.7)  1 (1.7) 6 (3.2)  
Transmission risk group, n (%)     <0.0001     0.3513 
   Homo/bisexual male 10574 (29.2) 11825 (39.1)  2 (3.4) 7 (3.8)  
   Injecting drug user 4601 (12.7) 4887 (16.2)  1 (1.7) 2 (1.1)  
   Heterosexual  16831 (46.4) 10783 (35.7)  50 (86.2) 154 (83.2)  
   Mother-to-child 99 (0.3) 26 (0.1)  1 (1.7)    
   Unknown/Other 4147 (11.4) 2710 (9.0)  4 (6.9) 22 (11.9)  
Prior AIDS diagnosis n (%) 8743 (24.1) 7169 (23.7) 0.2250 10 (17.2) 42 (22.7) 0.3762 
cART regimen, n (%)     <0.0001     0.4099 
   2 NRTIs + 1PI/rtv  7541 (20.8) 6823 (22.6)  8 (13.8) 44 (23.8)  
   2 NRTIs + LPV/rtv or DRV/rtv  11048 (30.5) 11039 (36.5)  30 (51.7) 79 (42.7)  
   3 NRTIs 4547 (12.5) 2180 (7.2)  8 (13.8) 24 (13.0)  
   Other combinations 13116 (36.2) 10189 (33.7)  12 (20.7) 38 (20.5)  
Period of cART initiation, n (%)     <0.0001     0.6214 
   1998-1999 7883 (21.7) 6292 (20.8)  4 (6.9) 13 (7.0)  
   2000-2001 5476 (15.1) 3708 (12.3)  5 (8.6) 19 (10.3)  
   2002-2003 5921 (16.3) 3810 (12.6)  6 (10.3) 32 (17.3)  
   2004-2005 5519 (15.2) 4613 (15.3)  16 (27.6) 34 (18.4)  
   2006-2007 5835 (16.1) 5557 (18.4)  11 (19.0) 44 (23.8)  
   2008-2009 5064 (14.0) 5102 (16.9)  10 (17.2) 30 (16.2)  
   2010-2011 554 (1.5) 1149 (3.8)  6 (10.3) 13 (7.0)  
Legend: cART: combination ART; LPV, lopinavir; DRV, darunavir, Other combinations: mainly 2 or 3 NRTIs plus an unboosted PI and combinations with an integrase inhibitor.* Patients fulfilling 
inclusion criteria.
a
 Categorical variables were compared between excluded and included patients using Chi-Square tests or Fisher’s tests as appropriate. Quantitative variables (i.e. age) were 
compared using the Wilcoxon-Mann-Withney test between excluded and included patients. 
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